RSV

Clinical-stage biopharmaceutical company Novavax has begun enrolment in the phase two dose-ranging trial of its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age.

The randomised, blinded, placebo-controlled study is designed to evaluate the immunogenicity and safety of two dose levels of Novavax’s RSV-F protein nanoparticle vaccine, with and without aluminum phosphate as an adjuvant.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Novavax senior vice president and chief medical officer Gregory Glenn said the study will determine the optimal dosing regimen for future studies and the potential adjuvant effect of aluminum phosphate besides the evaluation of the safety and immunogenicity of RSV vaccine candidate in an important patient population.

"Previous clinical and preclinical findings have suggested that immunization with our nanoparticle vaccine produces functional neutralizing antibodies to multiple sites on the F protein," Glenn added.

"We expect to report top-line results from this trial, through day 56 observations, in the first quarter of 2013."

See Also:

The study is being conducted in collaboration with PATH, an international nonprofit organisation that will fund approximately $2m to support the trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Around 330 women of childbearing age are expected to be enrolled in the study and will receive either one or two intramuscular injections at each dose level of vaccine or placebo at days 0 and 28.

According to the study design, the safety and immunogenicity will be evaluated over six and four month periods, respectively.

Image: The electron micrograph of the Respiratory Syncytial Virus (RSV) pathogen. Credit: CDC/ Dr. Erskine Palmer.